Cannabis and Epilepsy: How CBD Became an FDA-Approved Treatment

## The Short Answer Cannabis and epilepsy have one of the more clinically-established relationships in the cannabis-medicine space. Epidiolex, a purified plant-derived CBD pharmaceutical, was approved by the FDA in 2018 for the treatment of specific rare, severe childhood-onset epilepsy syndromes (Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex). This is the first, and as of early 2026, one of the only — FDA-approved medications derived directly from the cannabis plant. ## What Epidiolex Is Epidiolex is a purified CBD solution manufactured under pharmaceutical standards. It is: - Plant-derived from hemp. - Highly purified (over 98 percent CBD). - Prescribed by neurologists for the approved indications. - Covered by insurance for the approved indications. - Tested in large-scale randomized controlled trials that demonstrated seizure-frequency reduction. ## Which Epilepsy Syndromes It Treats The three approved indications: **Dravet syndrome.** A rare, severe, treatment-resistant childhood epilepsy with multiple seizure types and significant developmental impact. **Lennox-Gastaut syndrome.** Another severe childhood-onset epilepsy with multiple seizure types and often significant cognitive involvement. **Tuberous sclerosis complex (TSC).** A genetic condition that can cause seizures (along with other manifestations). Epidiolex is approved for patients one year and older with these conditions. It is not approved for general epilepsy, adult-onset seizure disorders, or other neurological conditions. ## The Research Behind the Approval Epidiolex approval followed multiple randomized, placebo-controlled trials showing statistically significant reductions in seizure frequency. Key findings: - **Reduction in seizure frequency** across all three indications. - **Some patients saw dramatic responses;** others had minimal response. - **Side effects** include drowsiness, decreased appetite, diarrhea, liver-enzyme elevations in some patients (requiring monitoring). - **Drug interactions** with other seizure medications, particularly clobazam, require careful dose management. ## Why This Matters for Other Conditions Epidiolex's approval: - **Validates the clinical-research pathway** for cannabis-derived medications. - **Demonstrates that rigorous trials are possible** despite federal Schedule I status. - **Provides a model** for other cannabis-derived pharmaceuticals. - **Doesn't translate to general endorsement** of non-pharmaceutical CBD for other conditions, the approval is for specific indications, not CBD in general. ## CBD for Non-Approved Indications Consumer CBD products are sometimes marketed with seizure-related claims. Important distinctions: - **Epidiolex** is a pharmaceutical dosed under medical supervision at levels typically 5 to 25 mg/kg/day. - **Consumer CBD products** are sold at much lower doses with no pharmaceutical QC. - **Non-Epidiolex CBD for the approved epilepsy indications** is not recommended substitution; patients should use the approved medication under neurologist supervision. ## Cannabis (Not Just CBD) for Epilepsy THC-containing cannabis products have been studied for some seizure conditions with less consistent results. Some parents of children with severe epilepsy have pursued whole-plant or high-CBD cannabis under state medical programs before Epidiolex approval. The clinical picture is complex and individualized. ## Where to Go Next Related reading: [medical cannabis 101](/blog/medical-cannabis-101-qualifying-conditions-access-and-what-to-expect), [cbd oil benefits](/blog/cbd-oil-benefits-what-the-research-supports-and-what-it-doesnt), and [full-spectrum vs broad-spectrum vs isolate](/blog/full-spectrum-vs-broad-spectrum-vs-isolate-cbd-which-is-right-for-you). --- *This article is consumer education for adults 21+. Nothing here is medical, legal, or financial advice. Cannabis laws vary by state, always verify your state's current rules and, for health questions, consult a licensed clinician. For regulated New York retail, verify licensing via the OCM QR-code system at [cannabis.ny.gov](https://cannabis.ny.gov).*